banner
 
bar

program

slides
bar
 
 

Cardiovascular Risk Reduction in Patients with Type 2 Diabetes

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 17, 2012 through July 17, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all five segments totaling 2 hours and 10 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in type 2 diabetes.

Release Date

July 17, 2012

Expiration Date

July 17, 2014

Intended Audience

This program is intended for all primary care, internal medicine, and endocrinology specialists, as well as other healthcare providers caring for patients with diabetes.

Registration

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logoThis CME activity is supported by an
educational grant from Genentech

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosure

A. MICHAEL LINCOFF, MD
PROGRAM CHAIRMAN

Vice Chairman, Department of Cardiovascular Medicine
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Consultant: AstraZeneca, Avanir, Baxter, Bristol-Myers Squibb, Ikaria, Roche, Merck/Schering-Plough
Research Support: Anthera, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Kai Pharmaceuticals, Pfizer, Roche, Novartis, Sanofi-aventis, Merck/Schering-Plough, Scios, Takeda, Johnson & Johnson


JORGE PLUTZKY, MD
Director, The Vascular Disease Prevention Program Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consultant: Abbott Laboratories; Amylin Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ChemoCentryz Inc.; Daiichi Sankyo, Inc.; Genentech, Inc.; GlaxoSmithKline; Novo Nordisk; Orexigen Therapeutics, Inc.; Roche; Takeda Pharmaceuticals North America, Inc.; Theratechnologies, Inc.


ROBERT H. ECKEL, MD
Director of the Lipid Clinic
University of Colorado Hospital
Professor of Medicine
University of Colorado Anschutz Medical Campus
Director Lipid Clinic, University Hospital
Denver, CO

Nothing to disclose

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this educational activity, participants should:

  • Describe advances in therapeutic strategies based on new mechanisms, involving dual peroxisome proliferator-activated receptor-alpha/gamma (PPAR) agonism, on cardiometabolic markers, including lipids, triglycerides, HA1c, glucose levels, and microvascular disease.
  • Detail recent advances in our scientific understanding of mechanisms of action of dual peroxisome proliferator-activated receptor-alpha/gamma agonists, and how such agents might possess the necessary vasculopathy-mitigating effects—working through targeted lipid (LDL and triglyceride) and glycemic regulation, as well as other insulin-related mechanisms, including insulin resistance—to reduce the incidence of cardiovascular mortality, non-fatal myocardial infarction and stroke in patients with type 2 diabetes, especially in high-risk patient populations with a history of an ACS event and multiple associated with risk factors.
  • Summarize the relationship between T2DM and atherosclerosis and mechanisms that may play a role in mitigating the pro-thrombotic effects of this disease process; and how emerging therapies might affect signaling and inflammatory signals, including cytokines, inflammations, and insulin resistance, in the vasculopathic cascade that characterizes T2DM.
  • Describe the epidemiology, scope of problem, risk assessment, and risk-directed prevention-focused interventions that have been shown to optimize CV disease and stroke risk reduction in the setting of diabetes after ACS
  • Apply results from landmark trials, national guidelines from ADA, AACE, ACC and other organizations to the clinical challenge of multidimensional, multi-factorial CV risk reduction in the setting of high risk T2DM; especially, in patients who have sustained an ACS event and/or who have other risk factors for cardiovascular disease.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

ACCORD
ACS
Acute Coronary Syndrome
Adipocytes
Adiponectin
ALECARDIO
Aleglitazar
Aleglitazar
AMI
atherogenesis
Atherogenicity
Atherosclerotic Heart Disease
Atherothrombosis
BARI 2D Trial
Cardiometabolic
CHD
Clopidogrel
coronary heart disease

DCCT
Diabetes
Dual PPAR Agonists
dyslipidemia
Euro-Heart Survey
fenofibrate
Fibrate
FIELD
FPG
gemfibrozil
GIK
GLP-1
Glycemic Control
HbA1c
HDL,
HDL-C
Helsinki Heart Study
Hyperglycemia
Hyperglycemic

Insulin
ISAR-DIABETES
LDL
LDL-C
Lipid
MACE
Macrovascular
Muraglitazar
PERISCOPE
Peroxisome Proliferator-activator Receptors
Pioglitazone
PPAR
AMI
PPARa
PPARg
PPARd
PPAR-g agonism
Prasugrel

PROactive
Retinopathy Progression
Rosiglitazone
STENO-2
SYNCHRONY
HbA1c
SYNTAX
T2D
Glucose
T2DM
Tesaglitazar
Thiazolidinediones
triglyceride
Triglyceride/HDL-C
TRITON–TIMI 38
Type 2 Diabetes
TZD
Vascular Wall Disease